RxDoctor Payments Data

Martinique Lewis

Family · Chesapeake, VANPI 1851919708

Payments from drug & device makers

$3,530in general payments, 2019–2025

Across 162 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$606
  • AstraZeneca$301
  • Bayer$276
  • Jazz Pharmaceuticals Inc.$270
  • Nxstage Medical, Inc.$257
  • Akebia Therapeutics Inc$170
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,39796%
  • Education$1334%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,530 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$14,046
Medicare patients
108
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide93$282,197
AuryxiaFerric Citrate23$56,772
KerendiaFinerenone24$26,960
JardianceEmpagliflozin18$26,950
Sevelamer Carbonate71$17,111
Lanthanum Carbonate18$10,110
Midodrine Hcl30$2,594
Clonidine11$1,839
Losartan Potassium18$363
Lidocaine-PrilocaineLidocaine/Prilocaine11$226
Amlodipine Besylate33$148
Atorvastatin Calcium11$139
Carvedilol14$137
Pregabalin11$127
Allopurinol20$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$606$282,19793 claims
Akebia Therapeutics IncAuryxia$170$56,77223 claims
BayerKerendia$276$26,96024 claims
Boehringer IngelheimJardiance$74$26,95018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →